Xeris Biopharma Holdings (XERS) Total Debt Growth (1y) (2021 - 2026)
Xeris Biopharma Holdings (XERS) Total Debt Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | -11.90% |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -0.14% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 37.52% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | -10.56% |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -9.53% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -13.33% |
| 10 | Xeris Biopharma Holdings | 1.43 Bn | 1.32 Bn | 72.55 Mn | -8.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.48% |
| Dec 31, 2025 | -10.87% |
| Sep 30, 2025 | -5.11% |
| Jun 30, 2025 | -5.32% |
| Mar 31, 2025 | 4.78% |
| Dec 31, 2024 | 29.48% |
| Sep 30, 2024 | 11.23% |
| Jun 30, 2024 | 12.73% |
| Mar 31, 2024 | 13.88% |
| Dec 31, 2023 | 2.06% |
| Sep 30, 2023 | 50.13% |
| Jun 30, 2023 | 48.35% |
| Mar 31, 2023 | 47.18% |
| Dec 31, 2022 | 112.42% |
| Sep 30, 2022 | 57.91% |
| Dec 31, 2021 | 1.20% |